RxDoctor Payments Data

Craig Stewart, PA

Physician Assistant · Waterloo, ILNPI 1568472892

Payments from drug & device makers

$5,963in general payments, 2019–2025

Across 257 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Amgen$1K
  • Novartis$881
  • Johnson & Johnson$637
  • Merck$451
  • Impulse Dynamics (USA) Inc.$181
  • plus $916 from 14 others

What the payments were for

  • Travel & lodging$1,19520%
  • Food & beverage$4,72479%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,963 in reported general payments places this provider in the 95th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$93,737
Medicare patients
439
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$326,407
XareltoRivaroxaban286$322,767
Repatha SureclickEvolocumab164$125,755
EntrestoSacubitril/Valsartan68$102,141
FarxigaDapagliflozin Propanediol24$25,610
Praluent PenAlirocumab31$23,723
BrilintaTicagrelor16$13,134
VerquvoVericiguat11$7,173
DapagliflozinDapagliflozin Propanediol13$6,751
Metoprolol Succinate574$6,226
Rosuvastatin Calcium419$4,403
Atorvastatin Calcium467$3,509
Losartan Potassium368$2,543
Potassium Chloride142$1,995
Metoprolol Tartrate253$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$326,407327 claims
Johnson & JohnsonXarelto$637$322,767286 claims
NovartisEntresto$881$102,14168 claims
AstraZenecaFarxiga, Brilinta$142$38,74440 claims
MerckVerquvo$451$7,17311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Waterloo

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →